10-K · June 18, 2026
Grace Therapeutics, Inc. reported a significant decrease in net loss for the year ended March 31, 2026, totaling $7.8 million compared to $9.6 million in the previous year, driven by lower research and development…
Earnings analysis · 10-Q
GRCE earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, or MD&A financial data needed to assess revenue, margins, EPS, liquidity, or segment trends; those metrics are therefore…
Read full summary
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, or MD&A financial data needed to assess revenue, margins, EPS, liquidity, or segment trends; those metrics are therefore left null. Operational disclosure was limited to effective controls as of June 30, 2026, no material internal-control changes, and no material changes to previously disclosed risk factors. No quantitative financial guidance or forward operating outlook was provided.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, under Exchange Act Rules 13a-15(e) and 15d-15(e).
-
No material control changes
The company reported that no changes during the quarter ended June 30, 2026 materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
No insider trading-plan changes
No director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
What to watch
-
No updated risk-factor disclosure
Item 1A states that there have been no material changes from the risk factors disclosed in the Annual Report. The filing therefore provides no new quantified risk update for the quarter ended June 30, 2026.
-
Uncertain legal contingencies
Management notes that legal proceedings are inherently uncertain and that an unfavorable resolution could materially affect financial position, results of operations, or cash flows; however, the company states it is not currently party to proceedings likely to have a material adverse effect.
-
Controls cannot assure error prevention
The company cautions that its control system provides only reasonable, not absolute, assurance and cannot prevent all errors and fraud, despite concluding controls were effective as of June 30, 2026.
Management's outlook
No quantitative revenue or EPS outlook, operating forecast, or timing guidance was provided in the supplied 10-Q text.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.